TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36519287
Drug: 16-week concurrent
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16-week concurrent exercise program
Study: 36519749
Drug: Maintenance nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance nivolumab SOC (480 mg 4 weekly)
Study: 36519749
Drug: Extended interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended interval (480 mg 8 weekly)
Study: 36520251
Drug: Phase-Advance Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-Advance Intervention (PAI): 1 night of late-night wake therapy (LWT: sleep 9 pm-1 am) followed by 7 days of morning bright white light (BWL)
Study: 36520251
Drug: Phase-Delay Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase-Delay Intervention (PDI): 1 night of early-night wake therapy (EWT: sleep 3-7 am) plus 7 days of evening BWL
Study: 36520325
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (Boostrix) administered on or after the 27th week of pregnancy
Study: 36520325
Drug: No Tdap
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Tdap vaccine during pregnancy (control group)
Study: 36520426
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg plus Bevacizumab 15 mg/kg on day 1 of each 21-day cycle until disease progression or unacceptable toxic effects.
Study: 36520462
Drug: SB11 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB11 (0.5 mg)
Study: 36520462
Drug: RBZ (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBZ (0.5 mg)
Study: 36520715
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily for six additional weeks
Study: 36521131
Drug: Integrative couple
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative couple treatment for pathological gambling (ICT-PG)
Study: 36521131
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment approach
Study: 36521262
Drug: Inhaled single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled single-dose MK-5475 (120 μg and 360 μg)
Study: 36521262
Drug: Inhaled single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled single-dose MK-5475
Study: 36521501
Drug: Pegozafermin 3
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 3 mg once weekly
Study: 36521501
Drug: Pegozafermin 9
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 9 mg once weekly
Study: 36521501
Drug: Pegozafermin 18
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 18 mg once weekly
Study: 36521501
Drug: Pegozafermin 27
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 27 mg once weekly
Study: 36521501
Drug: Pegozafermin 18
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 18 mg once every 2 weeks
Study: 36521501
Drug: Pegozafermin 36
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 36 mg once every 2 weeks
Study: 36521580
Drug: Hydrodilatation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrodilatation with 40 mg triamcinolone acetonide (TA)
Study: 36521580
Drug: Hydrodilatation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrodilatation with 10 mg triamcinolone acetonide (TA)
Study: 36521694
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (identical appearance, intensity/frequency, and duration)
Study: 36522265
Drug: Toddler dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toddler dose of V114
Study: 36522265
Drug: Mixed regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed regimens with at least one infant dose plus toddler dose of V114
Study: 36522279
Drug: Biodynamic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodynamic drug response classifier (4-level classifier)
Study: 36522279
Drug: Standard-of-care cytotoxins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care cytotoxins (gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Study: 36522365
Drug: Mogamulizumab (anti-CCR4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (anti-CCR4 monoclonal antibody)
Study: 36522606
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dapagliflozin daily
Study: 36522767
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine plus paracetamol
Study: 36523415
Drug: Bivalent SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (5 μg of D614 and 5 μg of B.1.351)
Study: 36524116
Drug: CD38-directed CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD38-directed CAR-T cell therapy
Study: 36524557
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of maternal characteristics (age, BMI, history of GDM, family history of diabetes) with HbA1c and random plasma glucose.
Study: 36524810
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (inert pill)
Study: 36524810
Drug: No-treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment arm
Study: 36525180
Drug: TEC (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEC (docetaxel 75 mg/m2, epirubicin, and cyclophosphamide)
Study: 36525180
Drug: TECM (docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TECM (docetaxel, epirubicin, cyclophosphamide with metformin)
Study: 36525338
Drug: Esketamine plus
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine plus a newly initiated oral antidepressant
Study: 36525493
Drug: Anti-EGFR antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-EGFR antibody combined with neoadjuvant chemotherapy
Study: 36525493
Drug: Anti-EGFR antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-EGFR antibody
Study: 39051653
Drug: Adjuvant hepatic
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX
Study: 36525620
Drug: TA (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA (Treatment A)
Study: 36525620
Drug: Other ablation
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other ablation treatments
Study: 36525797
Drug: MEDPass (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDPass (50 ml of ONS four times per day with medication rounds)
Study: 36525797
Drug: Conventional ONS
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ONS administration (between meals)
Study: 36525797
Drug: Conventional ONS
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ONS administration
Study: 36525851
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) + Fitbit
Study: 36525851
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) + Fitbit
Study: 36525985
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg (two capsules on day 1 followed by one capsule daily for 4 days)
Study: 36526425
Drug: Language therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language therapy for 6 weeks
Study: 36526425
Drug: Therapy outcome
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy outcome scores
Study: 36526481
Drug: Preoperative dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative dexamethasone (1 mg/kg)
Study: 36526521
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg daily) for 6 weeks prior to nephrectomy
Study: 36526577
Drug: Positron emission
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomographic (PET) and computed tomographic (CT) imaging using a novel glycoprotein IIb/IIIa receptor antagonist-based radiotracer
Study: 36526815
Drug: Atovaquone treatment
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone treatment (Cohort 1, n=14)
Study: 36526815
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Cohort 2, n=15)
Study: 36527025
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg RT234
Study: 36527025
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg RT234
Study: 36527143
Drug: Oral bolus
Normalized name: phenylbutazone 1000 MG Oral Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bolus of 100,000 IU with 10,000 IU/week of vitamin D
Study: 36527367
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of cross-linked hyaluronic acid (HANOX-M-XL)
Study: 36527702
Drug: Treatment failure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failure (TF) in C1
Study: 36528039
Drug: Oral favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral favipiravir plus standard care (1800 mg twice daily for 1 day; 800 mg twice daily for 9 days)
Study: 36528039
Drug: Oral favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral favipiravir plus standard care (in patients younger than 60 years)
Study: 36528039
Drug: Oral favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral favipiravir plus standard care
Study: 36528053
Drug: Telemedicine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine and medication delivery service (TMDS) called 'MotoMeds'
Study: 36528376
Drug: Emraclidine 30
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emraclidine 30 mg once daily
Study: 36528376
Drug: Emraclidine 20
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emraclidine 20 mg twice daily
Study: 36528443
Drug: DTaP-IPV-HB-PRP∼T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRP∼T vaccine (Hexyon™, Sanofi) administered at 8, 12, 16 weeks and booster at 13 months (preterm) or 15 months (term)
Study: 36528522
Drug: BI 1810631
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1810631 (15 mg BID, escalating doses)
Study: 36528522
Drug: BI 1810631
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1810631 (escalating doses)
Study: 36528793
Drug: AZD8601 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8601 (3 mg total, 30 epicardial injections)
Study: 36529052
Drug: CoronaVac (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (first dose on D0, second dose on D28, booster dose on D210)
Study: 36529052
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of CoronaVac (D240)
Study: 36529089
Drug: Extended-release calcifediol
Normalized name: calcifediol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release calcifediol (ERC) 300 mcg on days 1-3 and 60 mcg on days 4-27
Study: 36529145
Drug: Overall treatment-related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment-related serious adverse events
Study: 36529145
Drug: Treatment-emergent deaths
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent deaths during induction
Study: 36529145
Drug: Treatment-emergent deaths
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent deaths during maintenance after HSCT
Study: 36529152
Drug: Sequential transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential transarterial chemoembolisation (TACE) followed by stereotactic body radiotherapy (27·5-40·0 Gy in five fractions) and avelumab (10 mg/kg) administered 14 days after radiotherapy and every 2 weeks thereafter.
Study: 36529613
Drug: Single-agent regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-agent regorafenib (RegI)
Study: 36529709
Drug: IV lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV lacosamide infusion (2-12 mg/kg/day or 100-600 mg/day; 15-60 minutes infusion)
Study: 36529709
Drug: IV lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV lacosamide infusion
Study: 36529811
Drug: Dupilumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab plus topical corticosteroids (200 mg for 5 kg to < 15 kg; 300 mg for 15 kg to < 30 kg) every 4 weeks for 16 weeks
Study: 36529949
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin
Study: 36530003
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with dignity
Study: 36531070
Drug: Nano-Pulse Stimulation™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-Pulse Stimulation™ (NPS™) therapy
Study: 36531460
Drug: Lactobacilli-loaded vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli-loaded vaginal capsules (one capsule per day for 10 days)
Study: 36531460
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule per day for 10 days)
Study: 36531900
Drug: Maintenance tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maintenance tobramycin inhalation solution (TIS) once daily
Study: 36532014
Drug: CD19-directed Piggy
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-directed Piggy Bac CAR T cell therapy (pbCAR-T)
Study: 36532031
Drug: ChAd63 MVA
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63 MVA ME-TRAP vaccine
Study: 36532058
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of subcutaneous atacicept
Study: 36532058
Drug: Weekly administrations
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administrations of atacicept for one year
Study: 36532058
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of atacicept
Study: 36532545
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g eicosapentaenoic acid (EPA) + 1.2 g docosahexaenoic acid (DHA)/day for 6 months
Study: 36532582
Drug: Dermal vacuum
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal vacuum massage therapy (as an adjunct to the main intervention).
Study: 36533429
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (cisplatin + 5-fluorouracil or capecitabine)
Study: 36533622
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment plus endovascular treatment (EVT)
Study: 36533798
Drug: DaxibotulinumtoxinA-lanm for
Normalized name: daxibotulinumtoxinA-lanm
Approvals — FDA: no, EMA: no, PMDA: no
Description: DaxibotulinumtoxinA-lanm for injection (DAXI) 40U (glabellar), 32U (forehead), 48U (lateral canthal)
Study: 36533948
Drug: Adjuvanted, inactivated
Normalized name: Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted, inactivated vaccines
Study: 36533948
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza virus vaccine
Study: 36533948
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccines without adjuvant
Study: 36534208
Drug: Tofacitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib monotherapy
Study: 36534274
Drug: Ofatumumab 20
Normalized name: ofatumumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 20 mg subcutaneously
Study: 37265222
Drug: Semaglutide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide treatment
Study: 36534474
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of antibiotics after culture
Study: 36534474
Drug: Specimen-initiated antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specimen-initiated antibiotic protocol
Study: 36534717
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg administered after delivery
Study: 36534825
Drug: IFX s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFX s.c. 120 mg every 2 weeks
Study: 36534825
Drug: IFX i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFX i.v. 3 mg/kg every 8 weeks
Study: 36534942
Drug: Crizotinib (CZ)
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib (CZ) with chemotherapy
Study: 36534976
Drug: DART (Decision-Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: DART (Decision-Aid for Renal Therapy)
Study: 37149056
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus olanzapine
Study: 36535196
Drug: Chemoradiotherapy (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (50 Gy, 2 Gy/f, 5 weeks with capecitabine: 800 mg/m2)
Study: 36535300
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg daily
Study: 36535524
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 or 300 mg every 2 weeks up to 52 weeks
Study: 36535765
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) intervention with individualized exercise prescription and mHealth device providing heart rate-based just-in-time (JIT) feedback on PA intensity.
Study: 36535765
Drug: Healthy aging
Normalized name: CVS Healthy Aging Probiotic Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy aging education condition with a reading prescription and weekly quizzes.
Study: 36535779
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with Aspirin
Study: 36536016
Drug: Comprehensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive intervention package including monthly food vouchers for eggs, milk, semolina, sugar, and oil, multiple micronutrient powder (MNP), counseling on child feeding and handwashing.
Study: 36536114
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (0.25 g/kg fat free mass)
Study: 36536114
Drug: Cricket protein
Normalized name: cricket allergenic extract
DrugBank: Acheta domesticus (DB10866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cricket protein (0.25 g/kg fat free mass)
Study: 36536114
Drug: Pea protein
Normalized name: Pea Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea protein (0.25 g/kg fat free mass)
Study: 36536364
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2 g per day for 8 weeks
Study: 36536916
Drug: Psilocybin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (single dose)
Study: 36537346
Drug: ABBV-47D11 (180,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-47D11 (180, 600, or 2400 mg)
Study: 36537346
Drug: ABBV-47D11 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-47D11 (600 mg or higher)
Study: 36537346
Drug: ABBV-47D11 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-47D11 (any dose)
Study: 36537742
Drug: KN015 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN015 (20 μg)
Study: 36537742
Drug: KN015 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN015 (40 μg)
Study: 36537742
Drug: KN015 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN015 (60 μg)
Study: 36537785
Drug: Psyllium (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (7.5 g per day)
Study: 36538098
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (no specific treatment for hypersalivation)
Study: 36538166
Drug: Passive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive therapy (n=14)
Study: 36538189
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + High-Intensity Laser Therapy (HILT)